Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Diabetic Foot Ulcers-Pipeline Review, H2 2016

Diabetic Foot Ulcers-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Diabetic Foot Ulcers-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers-Pipeline Review, H2 2016, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 16, 5, 16, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Diabetic Foot Ulcers.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Diabetic Foot Ulcers Overview 8

Therapeutics Development 9

Pipeline Products for Diabetic Foot Ulcers-Overview 9

Pipeline Products for Diabetic Foot Ulcers-Comparative Analysis 10

Diabetic Foot Ulcers-Therapeutics under Development by Companies 11

Diabetic Foot Ulcers-Therapeutics under Investigation by Universities/Institutes 13

Diabetic Foot Ulcers-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Diabetic Foot Ulcers-Products under Development by Companies 18

Diabetic Foot Ulcers-Products under Investigation by Universities/Institutes 21

Diabetic Foot Ulcers-Companies Involved in Therapeutics Development 22

ANP Technologies Inc 22

CardioVascular BioTherapeutics Inc 23

Celgene Corp 24

Chrysalis BioTherapeutics Inc 25

CytoTools AG 26

EyeGene Inc 27

FirstString Research Inc 28

Genentech Inc 29

GlaxoSmithKline Plc 30

Human Stem Cells Institute 31

Izun Pharmaceuticals Corp 32

Karyopharm Therapeutics Inc 33

Lakewood-Amedex Inc 34

Lytix Biopharma AS 35

Mallinckrodt Plc 36

MediWound Ltd 37

NovaLead Pharma Pvt Ltd 38

Oneness Biotech Co Ltd 39

Osiris Therapeutics Inc 40

Pherecydes Pharma SA 41

Plurogen Therapeutics Inc 42

TechnoPhage SA 43

TGV-Laboratories 44

Theravasc Inc 45

Topadur Pharma AG 46

USV Pvt Ltd 47

viDA Therapeutics Inc 48

ViroMed Co Ltd 49

Diabetic Foot Ulcers-Therapeutics Assessment 50

Assessment by Monotherapy Products 50

Assessment by Target 51

Assessment by Mechanism of Action 53

Assessment by Route of Administration 55

Assessment by Molecule Type 57

Drug Profiles 59

3K3A-APC-Drug Profile 59

ALLO-ASC-Drug Profile 61

ANP-017-Drug Profile 62

AP-102-Drug Profile 63

APO-2-Drug Profile 64

becaplermin biosimilar-Drug Profile 65

Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer-Drug Profile 66

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers-Drug Profile 68

CL-05-Drug Profile 69

CODA-001-Drug Profile 72

CVBT-141B-Drug Profile 74

Cyndacel-M-Drug Profile 75

daprodustat-Drug Profile 76

EG-Decorin-Drug Profile 78

epidermal growth factor biosimilar-Drug Profile 79

EscharEx-Drug Profile 80

esmolol hydrochloride-Drug Profile 82

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers-Drug Profile 83

Granexin-Drug Profile 84

Heberprot-P-Drug Profile 86

IMSP-001-Drug Profile 87

IZN-6D4-Drug Profile 88

LTX-109-Drug Profile 89

MT-003-Drug Profile 91

Mul-1867-Drug Profile 92

Neovasculgen-Drug Profile 93

Nu-2-Drug Profile 94

Nu-3-Drug Profile 95

ON-101-Drug Profile 97

OTI-1501-Drug Profile 99

PDA-002-Drug Profile 100

PluroGel N-Drug Profile 101

PP-2351-Drug Profile 102

Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers-Drug Profile 103

RG-7880-Drug Profile 104

rusalatide acetate-Drug Profile 105

selinexor-Drug Profile 108

sodium nitrite SR-Drug Profile 127

Stathmin-1-Drug Profile 129

TOPN-53-Drug Profile 130

TP-102-Drug Profile 131

V-10-Drug Profile 132

VM-202-Drug Profile 133

VTI-1000 Series-Drug Profile 137

VTI-3000 Series-Drug Profile 138

Diabetic Foot Ulcers-Dormant Projects 139

Diabetic Foot Ulcers-Discontinued Products 143

Diabetic Foot Ulcers-Product Development Milestones 144

Featured News & Press Releases 144

Appendix 153

Methodology 153

Coverage 153

Secondary Research 153

Primary Research 153

Expert Panel Validation 153

Contact Us 153

Disclaimer 154

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H2 2016 12

Number of Products under Development for Diabetic Foot Ulcers-Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Products, H2 2016 19

Assessment by Monotherapy Products, H2 2016 53

Number of Products by Top 10 Targets, H2 2016 54

Number of Products by Stage and Top 10 Targets, H2 2016 54

Number of Products by Top 10 Mechanism of Actions, H2 2016 56

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 56

Number of Products by Top 10 Routes of Administration, H2 2016 58

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 58

Number of Products by Top 10 Molecule Types, H2 2016 60

Number of Products by Stage and Top 10 Molecule Types, H2 2016 60

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H2 2016 12

Number of Products under Development for Diabetic Foot Ulcers-Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Development by Companies, H2 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Comparative Analysis by Unknown Stage Development, H2 2016 20

Products under Development by Companies, H2 2016 21

Products under Development by Companies, H2 2016 (Contd..1) 22

Products under Development by Companies, H2 2016 (Contd..2) 23

Products under Investigation by Universities/Institutes, H2 2016 24

Diabetic Foot Ulcers-Pipeline by ANP Technologies Inc, H2 2016 25

Diabetic Foot Ulcers-Pipeline by CardioVascular BioTherapeutics Inc, H2 2016 26

Diabetic Foot Ulcers-Pipeline by Celgene Corp, H2 2016 27

Diabetic Foot Ulcers-Pipeline by Chrysalis BioTherapeutics Inc, H2 2016 28

Diabetic Foot Ulcers-Pipeline by CytoTools AG, H2 2016 29

Diabetic Foot Ulcers-Pipeline by EyeGene Inc, H2 2016 30

Diabetic Foot Ulcers-Pipeline by FirstString Research Inc, H2 2016 31

Diabetic Foot Ulcers-Pipeline by Genentech Inc, H2 2016 32

Diabetic Foot Ulcers-Pipeline by GlaxoSmithKline Plc, H2 2016 33

Diabetic Foot Ulcers-Pipeline by Human Stem Cells Institute, H2 2016 34

Diabetic Foot Ulcers-Pipeline by Izun Pharmaceuticals Corp, H2 2016 35

Diabetic Foot Ulcers-Pipeline by Karyopharm Therapeutics Inc, H2 2016 36

Diabetic Foot Ulcers-Pipeline by Lakewood-Amedex Inc, H2 2016 37

Diabetic Foot Ulcers-Pipeline by Lytix Biopharma AS, H2 2016 38

Diabetic Foot Ulcers-Pipeline by Mallinckrodt Plc, H2 2016 39

Diabetic Foot Ulcers-Pipeline by MediWound Ltd, H2 2016 40

Diabetic Foot Ulcers-Pipeline by NovaLead Pharma Pvt Ltd, H2 2016 41

Diabetic Foot Ulcers-Pipeline by Oneness Biotech Co Ltd, H2 2016 42

Diabetic Foot Ulcers-Pipeline by Osiris Therapeutics Inc, H2 2016 43

Diabetic Foot Ulcers-Pipeline by Pherecydes Pharma SA, H2 2016 44

Diabetic Foot Ulcers-Pipeline by Plurogen Therapeutics Inc, H2 2016 45

Diabetic Foot Ulcers-Pipeline by TechnoPhage SA, H2 2016 46

Diabetic Foot Ulcers-Pipeline by TGV-Laboratories, H2 2016 47

Diabetic Foot Ulcers-Pipeline by Theravasc Inc, H2 2016 48

Diabetic Foot Ulcers-Pipeline by Topadur Pharma AG, H2 2016 49

Diabetic Foot Ulcers-Pipeline by USV Pvt Ltd, H2 2016 50

Diabetic Foot Ulcers-Pipeline by viDA Therapeutics Inc, H2 2016 51

Diabetic Foot Ulcers-Pipeline by ViroMed Co Ltd, H2 2016 52

Assessment by Monotherapy Products, H2 2016 53

Number of Products by Stage and Target, H2 2016 55

Number of Products by Stage and Mechanism of Action, H2 2016 57

Number of Products by Stage and Route of Administration, H2 2016 59

Number of Products by Stage and Molecule Type, H2 2016 61

Diabetic Foot Ulcers-Dormant Projects, H2 2016 142

Diabetic Foot Ulcers-Dormant Projects (Contd..1), H2 2016 143

Diabetic Foot Ulcers-Dormant Projects (Contd..2), H2 2016 144

Diabetic Foot Ulcers-Dormant Projects (Contd..3), H2 2016 145

Diabetic Foot Ulcers-Discontinued Products, H2 2016 146

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ANP Technologies Inc, CardioVascular BioTherapeutics Inc, Celgene Corp, Chrysalis BioTherapeutics Inc, CytoTools AG, EyeGene Inc, FirstString Research Inc, Genentech Inc, GlaxoSmithKline Plc, Human Stem Cells Institute, Izun Pharmaceuticals Corp, Karyopharm Therapeutics Inc, Lakewood-Amedex Inc, Lytix Biopharma AS, Mallinckrodt Plc, MediWound Ltd, NovaLead Pharma Pvt Ltd, Oneness Biotech Co Ltd, Osiris Therapeutics Inc, Pherecydes Pharma SA, Plurogen Therapeutics Inc, TechnoPhage SA, TGV-Laboratories, Theravasc Inc, Topadur Pharma AG, USV Pvt Ltd, viDA Therapeutics Inc, ViroMed Co Ltd

Diabetic Foot Ulcers Therapeutic Products under Development, Key Players in Diabetic Foot Ulcers Therapeutics, Diabetic Foot Ulcers Pipeline Overview, Diabetic Foot Ulcers Pipeline, Diabetic Foot Ulcers Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com